Azvudine HIV Protease inhibitor

Cat.No.E1243

Azvudine (RO-0622) is a novel nucleoside reverse transcriptase inhibitor with antiviral activity against human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), potently inhibits HIV-1 (EC50 range 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).
Azvudine HIV Protease inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 286.22

Quality Control

Batch: E124301 DMSO]57 mg/mL]false]Water]57 mg/mL]false]Ethanol]57 mg/mL]false Purity: 99.86%
99.86

Chemical Information, Storage & Stability

Molecular Weight 286.22 Formula

C9H11FN6O4

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1011529-10-4 -- Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 57 mg/mL ( (199.14 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 57 mg/mL

Ethanol : 57 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
HIV-1 [1]
(in antiviral activity assays)
0.03~ 6.92 nM(EC50)
HIV-2 [1]
(in antiviral activity assays)
0.018~ 0.025 nM(EC50)
HBV [1]
HCV [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05689034 Not yet recruiting
COVID-19 Respiratory Infection
Peking Union Medical College Hospital
January 20 2023 Phase 2|Phase 3
NCT05033145 Completed
COVID-19
HRH Pharmaceuticals Limited|GALZU INSTITUTE OF RESEARCH TEACHING SCIENCE AND APPLIED TECHNOLOGY Brazil|Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute
January 15 2022 Phase 3
NCT04668235 Completed
COVID-19
HRH Pharmaceuticals Limited|GALZU INSTITUTE OF RESEARCH TEACHING SCIENCE AND APPLIED TECHNOLOGY Brazil|UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE (UENF) Brazil
April 23 2021 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map